Zeo ScientifiX, Inc. (ZEOX): Revenue
$5.20M
Year ended 2025-10-31
$6.99M
Trailing 12 months to 2026-04-30
-7.1%
3-year compound annual growth
+11.2%
5-year compound annual growth
+42.8%
10-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-10-31 | $5.20M | +12.5% | 2026-01-29, From 2024-11-01 |
| 2024-10-31 | $4.62M | +1.4% | 2026-01-29, From 2023-11-01 |
| 2023-10-31 | $4.56M | -29.8% | 2025-01-29, From 2022-11-01 |
| 2022-10-31 | $6.49M | +16.0% | 2024-01-29, From 2021-11-01 |
| 2021-10-31 | $5.60M | +83.2% | 2023-02-14, From 2020-11-01 |
| 2020-10-31 | $3.06M | +79.5% | 2022-02-14, From 2019-11-01 |
| 2019-10-31 | $1.70M | +76.5% | 2021-02-08, From 2018-11-01 |
| 2018-10-31 | $964.5K | +69.3% | 2020-10-16, From 2017-11-01 |
| 2017-10-31 | $569.8K | +208.2% | 2020-03-06, From 2016-11-01 |
| 2016-10-31 | $184.9K | +25.2% | 2018-11-01, From 2015-11-01 |
| 2015-10-31 | $147.6K | +200.1% | 2017-07-07, From 2014-11-01 |
| 2014-10-31 | $49.2K | -40.7% | 2015-02-17, From 2013-11-01 |
| 2013-10-31 | $83.0K | -4.8% | 2015-02-17, From 2012-11-01 |
| 2012-10-31 | $87.1K | +382.0% | 2014-03-11, From 2011-11-01 |
| 2011-10-31 | $18.1K | n/a | 2013-02-13, From 2010-11-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | $5.20M | +12.5% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $5.64M | +35.8% |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $4.63M | +55.3% |
| Ocugen, Inc. (OCGN) | 2025-12-31 | $4.41M | +8.8% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $6.65M | -51.2% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $4.04M | +254.7% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $3.51M | -90.6% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $3.48M | -67.4% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $3.09M | -11.6% |
Compare ZEOX, DBVT, PRME, OCGN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗